248 related articles for article (PubMed ID: 26386666)
1. Surveillance of gram-positive cocci infections and drug resistance.
Li G; Hou S; Li Y; Liu S; Teng D; Hou D
Cell Mol Biol (Noisy-le-grand); 2015 Sep; 61(4):90-3. PubMed ID: 26386666
[TBL] [Abstract][Full Text] [Related]
2. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
3. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
Dowzicky MJ; Park CH
Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010).
Sader HS; Moet GJ; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):412-6. PubMed ID: 21546202
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea.
Hwang SH; Kim MN; Pai CH; Huh DH; Shin WS
Yonsei Med J; 2000 Oct; 41(5):563-9. PubMed ID: 11079615
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline Plus Ampicillin Against Gram-Positive Organisms: Results from E-Test Synergy Assays.
D'Arezzo S; Mazzarelli A; Venditti C; Nisii C; Petrosillo N; De Giuli C; Vulcano A; Paglia MG; Bordi E; Di Caro A; Taglietti F
Microb Drug Resist; 2017 Jun; 23(4):507-515. PubMed ID: 27526275
[TBL] [Abstract][Full Text] [Related]
8. Comparative activity of linezolid against staphylococci and enterococci isolated in Italy.
Stefani S; Mezzatesta ML; Tempera G; Debbra E; Schito AM; Nicoletti G; Marchére A
Clin Microbiol Infect; 2002 Jun; 8(6):368-72. PubMed ID: 12084106
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
Rybak MJ; Cappelletty DM; Moldovan T; Aeschlimann JR; Kaatz GW
Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.
Johnson AP; Warner M; Livermore DM
J Antimicrob Chemother; 2002 Jul; 50(1):89-93. PubMed ID: 12096011
[TBL] [Abstract][Full Text] [Related]
12. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of teicoplanin against gram-positive cocci.
Allouch P; Pina P; Chaplain C; Delarbre JM; Geffroy F; Grasmick CP; Marcolin M; Morel A; Pangon B; Rio Y; Sédaillan A
Pathol Biol (Paris); 2000 Oct; 48(8):792-5. PubMed ID: 11244609
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of Staphylococci and Enterococci to vancomycin and teicoplanin.
Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E
Adv Exp Med Biol; 2013; 788():125-32. PubMed ID: 23835969
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
[TBL] [Abstract][Full Text] [Related]
16. Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms.
Chen H; Wu W; Ni M; Liu Y; Zhang J; Xia F; He W; Wang Q; Wang Z; Cao B; Wang H
Int J Antimicrob Agents; 2013 Oct; 42(4):317-21. PubMed ID: 23880167
[TBL] [Abstract][Full Text] [Related]
17. [Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections].
Li JT; Li Y; Wang J;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):365-74. PubMed ID: 12820911
[TBL] [Abstract][Full Text] [Related]
18. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Gaona Álvarez C; Sánchez Silos RM; Hernández Rastrollo R; Martínez Tallo E; Cordero Carrasco JL
Rev Esp Quimioter; 2012 Mar; 25(1):25-30. PubMed ID: 22488538
[TBL] [Abstract][Full Text] [Related]
19. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
[TBL] [Abstract][Full Text] [Related]
20. Low Level of Resistance in Enterococci Isolated in Four Hospitals, Marseille, France.
Abat C; Raoult D; Rolain JM
Microb Drug Resist; 2016 Apr; 22(3):218-22. PubMed ID: 26247097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]